ISF35 Active Immunotherapy for Blood Cancer NIH Protocol - Alemtuzumab - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2013-12-31 14:02:52 T cells B-cell chronic lymphocytic leukemia Lymphocytic leukemia Hematologic neoplasms CD154 Leukemia Alemtuzumab Ofatumumab CD40 Medicine Immune system Oncology		ISF35 Active Immunotherapy for Blood Cancer NIH Protocol #[removed]Phase Ib Study of Autologous Ad-‐ISF35-‐Transduced CLL B Cells and Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Subjects with Fludarabin Add to Reading List Source URL: osp.od.nih.gov Download Document from Source Website File Size: 1,82 MB Share Document on Facebook

	Interim statement from the BCSH CLL Guidelines Panel George A Follows1, Adrian Bloor2, Claire Dearden3, Steve Devereux4, Christopher P Fox5, Peter Hillmen6, Ben Kennedy7, Helen McCarthy8, Nilima Parry-Jones9, Piers EM Pa DocID: 1qeKO - View Document
	Text mining workflow for extraction of paragraphs from full articles describing drug-gene interactions to support Onco KEM software platform for personalized treatments Fanny Perraudeau, David Morley, Mohammad Afshar, Ma DocID: 1aeJg - View Document
	Legend Non-Hodgkin Lymphoma (NHL) Open to AccrualPh 2b Open-label, Randomized Two Arm Study of Selinexor plus Low DocID: 18GfX - View Document
	PDF Document DocID: 17bbg - View Document
	Q&A GENMAB 16. august 2012 Med CEO Jan Van de Winkel Transcript Live Q and A Genmab CEO Jan Van de Winkel, 16. august 2012 Akademikeren DocID: 16VF9 - View Document